WO2026046046 - AVATROMBOPAG AND NEW THERAPEUTIC USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/046046
Publication Date
05.03.2026
International Application No.
PCT/CN2025/116226
International Filing Date
21.08.2025
Title **
[English]
AVATROMBOPAG AND NEW THERAPEUTIC USE THEREOF
[French]
AVATROMBOPAG ET SA NOUVELLE UTILISATION THÉRAPEUTIQUE
[Chinese]
阿伐曲泊帕及其新治疗用途
Applicants **
LI, Xinrui
Inventors
LI, Xinrui
Priority Data
202411178024.6
26.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1574 | |
| EPO | Filing, Examination, Granting | 8715 | |
| Japan | Filing, Examination, Granting | 1961 | |
| South Korea | Filing, Examination, Granting | 1654 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,644
Contact Us
Abstract[English]
The present disclosure relates to avatrombopag and new therapeutic use thereof. Specifically, the present disclosure relates to use of avatrombopag and a pharmaceutically acceptable salt thereof in the preparation of a drug, wherein the drug is used for treating breast cancer, and the pharmaceutically acceptable salt is selected from: maleate, tosylate, hydrochloride, succinate, sulfate, fumarate, acetate, phosphate, and citrate. The avatrombopag and the pharmaceutically acceptable salt thereof can effectively inhibit the level and activity of MET.[French]
La présente divulgation concerne de l'avatrombopag et une nouvelle utilisation thérapeutique de celui-ci. Plus particulièrement, la présente divulgation concerne l'utilisation d'avatrombopag et d'un sel pharmaceutiquement acceptable de celui-ci dans la préparation d'un médicament, le médicament étant utilisé pour traiter le cancer du sein, et le sel pharmaceutiquement acceptable étant sélectionné parmi : le maléate, le tosylate, le chlorhydrate, le succinate, le sulfate, le fumarate, l'acétate, le phosphate et le citrate. L'avatrombopag et son sel pharmaceutiquement acceptable peuvent inhiber efficacement le niveau et l'activité de MET.[Chinese]
本公开涉及阿伐曲泊帕及其新治疗用途。具体而言，本公开涉及阿伐曲泊帕及其药学上可接受的盐在制备药物中的用途，所述药物用于治疗乳腺癌；所述药学上可接受的盐选自：马来酸盐、甲苯磺酸盐、盐酸盐、琥珀酸盐、硫酸盐、富马酸盐、醋酸盐、磷酸盐、枸橼酸盐。阿伐曲泊帕及其药学上可接受的盐可以有效抑制MET的水平和活性。